Evaluating the effects of the novel GLP1 analogue, Liraglutide, in patients with Alzheimer's Disease (ELAD study): a randomised, double-blind, placebo-controlled trial.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 12 Jun 2019
At a glance
- Drugs Liraglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Acronyms ELAD
- 06 Jun 2019 Planned End Date changed from 1 Mar 2019 to 1 Dec 2019.
- 06 Jun 2019 Planned primary completion date changed from 1 Mar 2019 to 1 Dec 2019.
- 06 Jun 2019 Status changed from recruiting to active, no longer recruiting.